香港大學

創新技術

Gamma-delta T Cell Extracellular Vesicle-based Tumor Vaccines

(內容請參閱英文版)

This innovative cancer vaccine platform harnesses gamma-delta T cells - a rare immune cell type with natural tumor-targeting abilities. These natural biological messengers deliver targeted cancer signals to train the body's immune system to recognise and destroy tumors. Combining potent anti-tumor effects with ready-to-use convenience, this technology offers a scalable, effective treatment platform applicable across multiple cancer types with significant clinical and commercial potential.

Principal Investigator(s)

Team of Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine

 

Prof. Wenwei TU

Professor

 

Dr. Xiewang WANG

Research Assistant Professor

 

Dr. Yiping LIU

Research Officer

 

Email: wutw@hkuhk, xiewang@connect.hku.hk

Achievements and Awards

Gold Medal with Jury Congratulation, International Exhibition of Inventions Geneva 2025

Learn More About This Technology Offering: